Treating Progressive-relapsing MS (PRMS) - National Multiple Sclerosis Society

Skip to navigation Skip to content

Treating PRMS


Modifying the Disease Course

The interferon beta medications (Avonex®, Betaseron® and Rebif®) and Tysabri® (natalizumab) are approved by the U.S. Food & Drug Administration (FDA) for use in relapsing forms of MS, which includes progressive-relapsing MS. If you and your healthcare team feel that the interferon medication does not adequately control disease activity, your physician will likely recommend changing to Novantrone® (mitoxantrone).

Managing symptoms

Regardless of the course of MS a person is experiencing, proactive symptom management is essential to maintaining comfort and productivity, and enhancing quality of life.


Rehabilitation specialists have an important role, from the time of diagnosis onward, in helping people function optimally in spite of their MS; enhancing mobility and promoting safety and independence